Form 8-K - Current report:
SEC Accession No. 0001104659-26-040387
Filing Date
2026-04-07
Accepted
2026-04-07 16:15:24
Documents
13
Period of Report
2026-04-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2611268d1_8k.htm   iXBRL 8-K 24008
2 EXHIBIT 99.1 tm2611268d1_ex99-1.htm EX-99.1 16251
6 GRAPHIC tm2611268d1_ex99-1img001.jpg GRAPHIC 4988
  Complete submission text file 0001104659-26-040387.txt   217929

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20260407.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20260407_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20260407_pre.xml EX-101.PRE 22380
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2611268d1_8k_htm.xml XML 3193
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 26845106
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)